Goebeler, Maria-Elisabeth
Bargou, Ralf C. http://orcid.org/0000-0002-1221-7421
Article History
Accepted: 26 February 2020
First Online: 2 April 2020
Competing interests
: M.-E.G. has consulted for and received honoraria from Gemoab. R.C.B. has consulted for and received honoraria from Amgen, Cellex and Gemoab. R.C.B. is patent holder for blinatumomab, from which he receives royalty payments. M.-E.G and R.C.B. have both received honoraria for serving on the advisory boards of Amgen, Bristol-Myers Squibb, Gemoab, Novartis and Roche.